Page 4 - Therapeutic Development Programs News Today

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSEAMERICAN:NAVB opened at $0.09 on Tuesday. The business’s 50 day simple moving average is $0.13 and its […]

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Free Report) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance NYSEAMERICAN NAVB opened at $0.09 on Friday. The firm has a 50 day simple moving average of $0.14 and a […]

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a report issued on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Price Performance Shares of NYSEAMERICAN:NAVB opened at $0.10 on Friday. The business’s fifty day moving average price is $0.14 and its two-hundred day […]

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a report released on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance NYSEAMERICAN:NAVB opened at $0.10 on Friday. The stock’s fifty day moving average price is $0.15 and its two-hundred day moving average […]

Stock analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report released on Sunday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Price Performance About Navidea Biopharmaceuticals (Get Rating) Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents […]

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a research report released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSEAMERICAN:NAVB opened at $0.10 on Wednesday. The stock has a 50 day moving average of $0.15 and a 200 […]

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Price Performance NYSEAMERICAN:NAVB opened at $0.10 on Tuesday. Navidea Biopharmaceuticals has a 52 week low of $0.07 and a 52 […]

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a research report released on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Price Performance NAVB stock opened at $0.10 on Tuesday. The company has a fifty day moving average price of $0.16 and a […]

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a research report report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Trading Up 7.8 % Shares of NAVB stock opened at $0.10 on Monday. The stock has a 50 day moving average […]

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Get Rating) in a report issued on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Price Performance Shares of NYSEAMERICAN:NAVB opened at $0.09 on Monday. The company’s fifty day moving average price is $0.16 and its 200-day moving […]